This review article discusses the role of damage-associated molecular patterns (DAMPs) in modulating Toll-like receptor (TLR) signaling and their involvement in inflammatory and autoimmune diseases. DAMPs are endogenous molecules released by damaged or necrotic cells, which act as danger signals to alert the immune system to tissue injury. They can activate TLRs, leading to inflammatory gene expression and tissue repair. However, excessive TLR activation by DAMPs can contribute to chronic inflammation and disease pathogenesis, including rheumatoid arthritis, cancer, and atherosclerosis. DAMPs include intracellular molecules released into the extracellular environment and extracellular matrix molecules that are upregulated upon tissue injury. They can activate TLRs through various mechanisms, often requiring co-receptors or accessory molecules. Examples of DAMPs include heat shock proteins (HSPs), high-mobility group box-1 (HMGB1), and fragments of extracellular matrix molecules. These DAMPs can induce distinct signaling pathways and biological outcomes compared to pathogen-associated molecular patterns (PAMPs), which are recognized by TLRs in response to microbial products. TLR signaling pathways activated by DAMPs and PAMPs differ in their mechanisms of recognition and downstream effects. DAMPs can activate TLRs through different co-receptors and accessory molecules, leading to distinct inflammatory responses. For example, HMGB1 can activate TLR4 through CD14 and MD-2, while other DAMPs may require different co-receptors. The signaling pathways initiated by DAMPs include the MyD88-dependent and TRIF-dependent pathways, which lead to the activation of transcription factors such as NF-κB and IRF, resulting in the production of inflammatory cytokines and chemokines. The review highlights the potential therapeutic applications of targeting DAMPs to reduce inflammation without broadly suppressing the immune system. Inhibiting DAMP activity has been shown to ameliorate disease in experimental models, including sepsis, arthritis, and atherosclerosis. Strategies for targeting DAMPs include blocking TLR activation, preventing DAMP accumulation, and modulating the release of intracellular DAMPs. These approaches may offer new therapeutic options for inflammatory and autoimmune diseases by specifically targeting DAMP-mediated TLR activation while preserving host defense mechanisms. The study also emphasizes the importance of understanding the differences between DAMP and PAMP signaling to develop targeted therapies that can effectively dampen inflammation without compromising immune function.This review article discusses the role of damage-associated molecular patterns (DAMPs) in modulating Toll-like receptor (TLR) signaling and their involvement in inflammatory and autoimmune diseases. DAMPs are endogenous molecules released by damaged or necrotic cells, which act as danger signals to alert the immune system to tissue injury. They can activate TLRs, leading to inflammatory gene expression and tissue repair. However, excessive TLR activation by DAMPs can contribute to chronic inflammation and disease pathogenesis, including rheumatoid arthritis, cancer, and atherosclerosis. DAMPs include intracellular molecules released into the extracellular environment and extracellular matrix molecules that are upregulated upon tissue injury. They can activate TLRs through various mechanisms, often requiring co-receptors or accessory molecules. Examples of DAMPs include heat shock proteins (HSPs), high-mobility group box-1 (HMGB1), and fragments of extracellular matrix molecules. These DAMPs can induce distinct signaling pathways and biological outcomes compared to pathogen-associated molecular patterns (PAMPs), which are recognized by TLRs in response to microbial products. TLR signaling pathways activated by DAMPs and PAMPs differ in their mechanisms of recognition and downstream effects. DAMPs can activate TLRs through different co-receptors and accessory molecules, leading to distinct inflammatory responses. For example, HMGB1 can activate TLR4 through CD14 and MD-2, while other DAMPs may require different co-receptors. The signaling pathways initiated by DAMPs include the MyD88-dependent and TRIF-dependent pathways, which lead to the activation of transcription factors such as NF-κB and IRF, resulting in the production of inflammatory cytokines and chemokines. The review highlights the potential therapeutic applications of targeting DAMPs to reduce inflammation without broadly suppressing the immune system. Inhibiting DAMP activity has been shown to ameliorate disease in experimental models, including sepsis, arthritis, and atherosclerosis. Strategies for targeting DAMPs include blocking TLR activation, preventing DAMP accumulation, and modulating the release of intracellular DAMPs. These approaches may offer new therapeutic options for inflammatory and autoimmune diseases by specifically targeting DAMP-mediated TLR activation while preserving host defense mechanisms. The study also emphasizes the importance of understanding the differences between DAMP and PAMP signaling to develop targeted therapies that can effectively dampen inflammation without compromising immune function.